- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00984971
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet (RMP02-MTN006)
A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults
To date, the majority of microbicide research has focused on the assessment of the safety and effectiveness of vaginal microbicides used for the prevention of HIV transmission via the vaginal compartment. Receptive anal intercourse (RAI) is common among men who have sex with men (MSM), and there is increasing evidence that heterosexual women in the developed and developing world also practice anal sex. It can, therefore, be anticipated that once vaginal microbicides are licensed, they will be used in both the vaginal and rectal compartments. As a consequence, there is a need to evaluate both the rectal and vaginal safety profile of candidate microbicides. Therefore, the primary objective of this study is to evaluate the systemic safety of 1% vaginally formulated tenofovir gel applied rectally. In addition, this study will evaluate the immunotoxicity of the gel and evaluate its acceptability; it will also use the oral tenofovir disoproxil fumarate tablets (TDF), rectally-applied tenofovir gel,and a placebo gel to compare their systemic and compartmental pharmacokinetic (pK) profiles.
This study was designed to address the following hypotheses:
- Vaginally-formulated tenofovir 1% topical gel when applied rectally will be safe using a combination of clinical and laboratory markers including assays specifically designed to measure mucosal toxicity
- Tenofovir will be detectable at different concentrations in the various anatomic compartments sampled for pharmacokinetics following single and 7-day topical exposures
- Exposure to tenofovir 1% gel will demonstrate prevention of ex vivo HIV-1 challenge using in vivo drug-exposed tissue as compared to baseline tissue samples
- Orally delivered, single dose, 300 mg tenofovir disoproxil fumarate tablets will have similar safety profiles using routine blood safety indices as have been established in other trials and will show no mucosal safety concerns
- The oral dose will have different multi-compartment concentration kinetics than the topical tenofovir and will also demonstrate preliminary (ex vivo) prevention using the explant infectivity assay
- Vaginally formulated tenofovir 1% topical gel applied rectally will be acceptable to participants, as indicated by a score in the upper one third of the 10-point Likert scale on intentionality to use in the product in the future
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90024
- UCLA Center for HIV Prevention Research
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- University of Pittsburgh Clinical Research Unit
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria
- ≥ Age of 18 at screening
- Willing and able to provide written informed consent for screening and enrollment
- HIV-1 uninfected at screening according to the standard DAIDS algorithm in Appendix II
- Willing and able to communicate in English
- Willing and able to provide adequate locator information, as defined in site standard operating procedures (SOP)
- Availability to return for all study visits, barring unforeseen circumstances
- Per participant report at screening, a history of consensual RAI at least once in the prior year
- Willing to abstain from insertion of anything rectally including sex toys, other than the study gel during the active phases of the study and for 5 days following biopsy collection
- Willing to abstain from sexual intercourse (rectal and vaginal) during the active phases of the study and for 5 days following biopsy collection
- Must agree to use study provided condoms for the duration of the study for vaginal and insertive anal intercourse
- Must be in general good health
Must agree not to participate in other drug trials
In addition to the criteria listed above, female participants must meet the following criteria:
- Post-menopausal or using (or willing to use) an acceptable form of contraception (e.g., barrier method, IUD, hormonal contraception, surgical sterilization, or vasectomization of male partner). If the female participant has female partners only, the method of contraception will be noted as a barrier method in the study documentation.
Exclusion Criteria
- Abnormalities of the colorectal mucosa, or significant colorectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids)
At screening, clinical or laboratory diagnosis of active rectal or reproductive tract infection requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines or urinary tract infection (UTI). Infections requiring treatment include symptomatic bacterial vaginosis, symptomatic vaginal candidiasis, other vaginitis, trichomoniasis, Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, pelvic inflammatory disease, genital sores or ulcers, cervicitis, or symptomatic genital warts requiring treatment. Note that HSV-2 seropositive with no active lesions is allowed, since treatment is not required.
Note: Allow one re-screening after documented treatment (30 days) in cases of GC/CT identified at screening
At screening:
- Positive for hepatitis B surface antigen
- Hemoglobin < 10.0 g/dL
- Platelet count < 100,000/mm3
- White blood cell count less than 2,000 cells/mm3 or > than 15,000 cells/mm3
- Calculated creatinine clearance less than 80 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min (140- age in years) x (weight in kg) x (0.85 for females)/72 x (serum creatinine in mg/dL)
- Serum creatinine > 1.3× the site laboratory upper limit of normal (ULN)
- ALT and/or AST > 2.5× the site laboratory ULN
- +1 glucose or +1 protein on urinalysis (UA)
- History of bleeding problems (i.e. INR > 1.5× the site laboratory ULN or PTT > 1.25× the site laboratory ULN)
- History of significant gastrointestinal bleeding in the opinion of the investigator
- Allergy to methylparaben, propylparaben, sorbic acid
- By participant report at enrollment, history of excessive daily alcohol use (as defined by the CDC as heavy drinking consisting of an average consumption of more than 2 drinks per day for men, and more than 1 drink per day for women), frequent binge drinking or illicit drug use that includes any injection drugs, methamphetamines (crystal meth), heroin, or cocaine including crack cocaine, within the past 12 months
Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications during the period of study participation:
- Heparin, including Lovenox®
- Warfarin
- Plavix® (clopidogrel bisulfate)]
- Rectally administered medications (including over-the-counter products)
- Aspirin
- NSAIDS
- Acyclovir
- Valacyclovir
- TDF
- Any other drugs that are associated with increased likelihood of bleeding following mucosal biopsy
- By participant report at screening, use of systemic immunomodulatory medications, rectally administered medications, rectally administered products (including condoms) containing N-9, or any investigational products within the 4 weeks prior to the Enrollment/Baseline Evaluation Visit
- History of recurrent urticaria
Any other condition or prior therapy that, in the opinion of the investigator, would preclude informed consent, make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease.
In addition to the criteria listed above, female participants will be excluded if they meet any of the following criteria:
- Pregnant at Enrollment/Baseline Evaluation Visit
- Breastfeeding or intent to breastfeed during duration of study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Tenofovir
|
Topical gel applied rectally
|
Komparator placebo: HEC Placebo
|
Placebo gel applied rectally
|
Inny: Open label tenofovir tablet
|
All participants will undergo an open label tenofovir tablet single dose administration (i.e.
Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Grade 2 or higher clinical and laboratory adverse events as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0,Dec 2004 and Addenda 1 and 3 to this table.
Ramy czasowe: Every study visit
|
Every study visit
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Immunotoxicity, Pharmacokinetics, and Acceptability
Ramy czasowe: Immunotoxicity and pharmacokinetics: every study visit; acceptability: baseline and end of study
|
Immunotoxicity and pharmacokinetics: every study visit; acceptability: baseline and end of study
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Richardson-Harman N, Hendrix CW, Bumpus NN, Mauck C, Cranston RD, Yang K, Elliott J, Tanner K, McGowan I, Kashuba A, Anton PA. Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One. 2014 Oct 28;9(10):e111507. doi: 10.1371/journal.pone.0111507. eCollection 2014.
- Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One. 2014 Oct 28;9(10):e106196. doi: 10.1371/journal.pone.0106196. eCollection 2014.
- Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, Elliott J, Janocko L, Khanukhova E, Dennis R, Cumberland WG, Ju C, Carballo-Dieguez A, Mauck C, McGowan I. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1412-21. doi: 10.1089/aid.2012.0262. Epub 2012 Oct 9.
- Richardson-Harman N, Mauck C, McGowan I, Anton P. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1422-33. doi: 10.1089/AID.2012.0073. Epub 2012 Sep 20.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby przenoszone drogą płciową, wirusowe
- Choroby przenoszone drogą płciową
- Infekcje lentiwirusowe
- Zakażenia Retroviridae
- Zespoły niedoboru odporności
- Choroby układu odpornościowego
- Zakażenia wirusem HIV
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Środki przeciwwirusowe
- Inhibitory odwrotnej transkryptazy
- Inhibitory syntezy kwasów nukleinowych
- Inhibitory enzymów
- Agenci przeciw HIV
- Środki przeciwretrowirusowe
- Tenofowir
Inne numery identyfikacyjne badania
- DAIDS ID 10769
- RMP02-MTN006
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Zakażenia wirusem HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutacyjnyHIV | Test na HIV | Związek HIV z opieką | Leczenie HIVStany Zjednoczone
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement i inni współpracownicyNieznanyHIV | Dzieci niezakażone wirusem HIV | Dzieci narażone na HIVKamerun
-
University of MinnesotaWycofaneZakażenia wirusem HIV | HIV/AIDS | HIV | AIDS | Problem z AIDS/HIV | AIDS i infekcjeStany Zjednoczone
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationZakończonyPartnerskie testy na obecność wirusa HIV | Porady dotyczące HIV dla par | Komunikacja pary | Zapadalność na HIVKamerun, Republika Dominikany, Gruzja, Indie
-
Hospital Clinic of BarcelonaZakończonyInhibitory integrazy, HIV; INHIB PROTEAZY HIVHiszpania
-
University of Maryland, BaltimoreWycofaneHIV | Przeszczep nerki | Zbiornik HIV | CCR5Stany Zjednoczone
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... i inni współpracownicyRekrutacyjnyHIV | Test na HIV | Połączenie z opiekąAfryka Południowa
-
CDC FoundationGilead SciencesNieznanyProfilaktyka przed ekspozycją na HIV | Chemioprofilaktyka HIVStany Zjednoczone
-
Erasmus Medical CenterJeszcze nie rekrutacjaZakażenia wirusem HIV | HIV | Zakażenie HIV-1 | Zakażenie wirusem HIV IHolandia
-
Helios SaludViiV HealthcareNieznanyHIV | Zakażenie HIV-1Argentyna
Badania kliniczne na Tenofovir
-
French National Agency for Research on AIDS and...Gilead Sciences; PharmassetZakończonyHBe ujemny Przewlekłe wirusowe zapalenie wątroby typu B | Wirusowe zapalenie wątroby typu BFrancja
-
Zhongshan Hospital (Xiamen), Fudan UniversityRekrutacyjnyRak wątrobowokomórkowy | Przewlekłe wirusowe zapalenie wątroby typu BChiny
-
National Center for Research Resources (NCRR)University of RochesterZakończonyMiopatia mitochondrialna
-
Ain Shams UniversityZakończonyCesarskie cięcie; Rozejście się | Nisza blizny po cesarskim cięciuEgipt
-
National Taiwan University HospitalMackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital i inni współpracownicyNieznany
-
Fundacion IDEAAViiV HealthcareZakończony
-
Charlotte-Paige Rolle, MDViiV HealthcareZakończonyZakażenie wirusem HIV IStany Zjednoczone
-
University of Colorado, DenverZakończonyZdrowi Wolontariusze | Farmakokinetyka
-
Massachusetts General HospitalGilead SciencesWycofaneZmęczenie | Stwardnienie rozsiane, rzutowo-remisyjneStany Zjednoczone
-
University of California, San DiegoAktywny, nie rekrutującyHIV | Terapia hormonalnaStany Zjednoczone